rHIgM22

Drug Profile

rHIgM22

Alternative Names: M22; Remyelinating-monoclonal-antibody-Acorda-Therapeutics; sHIgM22

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic
  • Developer Acorda Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 21 Sep 2017 Acorda Therapeutics completes a phase I trial in Multiple sclerosis in USA (IV) (NCT02398461)
  • 07 Sep 2016 rHIgM22 is still in phase I trials for Multiple sclerosis in USA (Acorda Therapeutics pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top